Recently, well-known multinational pharmaceutical companies Johnson and Johnson, Roche was exposed to news of layoffs. It is rumored that Johnson & Johnson's non-prescription department will carry out a round of layoffs at the end of December, 32 representatives and four regional managers face unemployment; the second round of layoffs will be carried out early next year, and the team of more than 179 people is expected to be streamlined to more than 90 people. Nearly half of the personnel will be abolished. Roche’s PEGASYS will also lay off staff, and employees have been interviewed. The details of the layoffs are temporarily unknown. In this news, Shi Dingchen, the founder of Beijing Dingchen Consulting, told the Health and Welfare Bureau that with the arrival of the patent cliff, the progress of research and development of new drugs is slow, the return on investment is uneven, and multinational pharmaceutical companies have made strategic adjustments. The most obvious strategic trend is to reposition the enterprise and focus on the dominant industry to help the company form a strong competitive and defensive posture in certain therapeutic areas. In order to reduce costs and ensure profits, many foreign pharmaceutical companies have implemented substantial layoffs, and some product lines have been merged or cancelled. The re-adjustment of these foreign-invested companies' business focus will inevitably lead to a large flow of many medical talents. The adjustment of various drug types will also reconstruct the pattern of the pharmaceutical market, and the market share of pharmaceutical companies on certain types of drugs will be rewritten. Talents, varieties, domestic pharmaceutical companies rush to take over At a time when foreign-funded pharmaceutical companies have severely laid off employees and adjusted their product mix, domestic pharmaceutical companies have also taken advantage of this to absorb foreign talents and varieties. In particular, the variety, because of the dual guarantee of the brand and the market, has become the object of high prices for domestic pharmaceutical companies. At present, there are two forms of domestic pharmaceutical companies' solutions. One is to sell directly to domestic pharmaceutical companies. For example, in May this year, China Tailing Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Tai Ling Pharmaceutical†"), announced that it has reached an agreement with Novartis Pharmaceuticals to acquire the undergraduate brand secrets, related intellectual property rights, licenses and other assets to the latter, for a total transaction amount of 145 million US dollars. According to the agreement, Tailing Pharmaceutical will obtain sales networks in China (including Hong Kong and Taiwan), South Korea, Southeast Asia, India and other major Asia-Pacific regions, as well as Switzerland, Australia, Russia, Brazil, South Africa and other parts of the world. According to the disclosure data of Tailing Pharmaceutical's 2015 annual report, the acquisition is expected to increase the annual sales of Tailing Pharmaceutical by more than 40%, and it has become a new important source of profit for the company. Another way is to unlock the right to sell. On November 9, Lilly China officially announced the sale of its antibiotic products and its distribution and promotion rights in the Chinese mainland market to Yiteng. The cooperation will begin on January 1, 2017. This is the fifth time this year that a multinational pharmaceutical company has established a product line in China to conduct commercial cooperation with local Chinese pharmaceutical companies. " Shi Lichen said that this is a rare market opportunity for domestic pharmaceutical companies. Domestic pharmaceutical companies should take the initiative to actively contact foreign-funded pharmaceutical companies because foreign-funded pharmaceutical companies hold too many expired patented drugs. With the gradual advancement of medical reform, the pressure is also growing. Once foreign pharmaceutical companies feel that the profit margin is insufficient, cooperation with domestic pharmaceutical companies has become a better choice. Once this opportunity is seized, it is yours. . The reason is that domestic pharmaceutical companies have their own advantages in low-cost marketing of generic drugs, and with their own team advantages, coupled with a good variety, they can quickly expand the market. For foreign sales personnel responsible for the promotion of this product, once the business is a variety of non-focus areas of the company, it is obvious that the company is difficult to tilt in resource allocation. Even if the individual is doing well, the future will be marginalized or even laid off. risk. Attachment: 9 multinational pharmaceutical giants focus on disease areas and existing key varieties (what varieties have opportunities/risks, you know) Shi Guibao Future Focus Areas: Immunotherapy (IO) in the field of cancer, China focuses on lung cancer, stomach cancer and liver cancer. Existing domestic layout: anti-hepatitis B virus drugs, oncology drugs, cardiovascular drugs, antibiotics Stripped business: 1. In 2014, 12 the diabetes business was sold to AstraZeneca and turned to the field of cancer. 2. In August 2016, the Department of Tumors was abolished and divested in the Huaxin Cerebrovascular Division, which will be the main biopharmaceutical in the future. Modified Soybean Pholipid,Modified Soybean Lecithin Oil,Modified Soy Lecithin Oil,Modified Soy Lecithin Jiangsu Chenwei Biology and Technology Co. LTD , https://www.cwsoybean.com